FTC and seven states seek contempt ruling against Shkreli over pharma ban
The FTC and seven US states are seeking a contempt ruling against Martin Shkreli for allegedly violating a lifetime ban from the pharmaceutical industry. The motion claims Shkreli has continued to trade stocks and influence business decisions since his 2022 release from prison.
Why it matters
This case highlights ongoing legal efforts to enforce regulatory bans on controversial figures in the pharmaceutical sector.
Martin Shkreli speaking to the press in 2017 after the jury issued a verdict in his case at the US direct court for the eastern district in New York City. Martin Shkreli speaking to the press in 2017 after the jury issued a verdict in his case at the US direct court for the eastern district in New York City. Martin Shkreli FTC and seven states seek contempt ruling against Shkreli over pharma ban Martin Shkreli’s 2022 release conditions bar him from participating in the pharmaceutical industry, including ownership stakes or business decisions
Prefer the Guardian on Google The Federal Trade Commission (FTC) and seven US states have alleged that pharmaceutical executive Martin Shkreli repeatedly violated a lifetime ban on participating in the pharmaceutical industry, and they are asking a judge to hold him in contempt.
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in